Nautilus Biotechnology, Inc.
NASDAQ:NAUT
1.76 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 5.705 | 3.416 | 2.842 | 2.346 | 0 | 0 |
| Gross Profit
| -5.705 | -3.416 | -2.842 | -2.346 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 47.251 | 37.672 | 29.352 | 12.432 | 0.008 | 0 |
| General & Administrative Expenses
| 28.901 | 25.946 | 21.146 | 3.312 | 0.002 | 111.684 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 28.901 | 25.946 | 21.146 | 3.312 | 0.002 | 111.684 |
| Other Expenses
| 0 | -0.122 | 0.183 | 0.125 | 0 | 0 |
| Operating Expenses
| 76.152 | 63.618 | 50.498 | 15.744 | 0.01 | 111.684 |
| Operating Income
| -76.152 | -63.618 | -50.498 | -15.744 | -0.01 | -111.684 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 12.477 | 5.694 | 0.183 | 0.125 | -9.608 | 738.284 |
| Income Before Tax
| -63.675 | -57.924 | -50.315 | -15.619 | -0.01 | 626.6 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 5.816 | 2.605 | 2.14 | -0.171 | 738.123 |
| Net Income
| -63.675 | -63.74 | -50.315 | -15.619 | -0.01 | 626.6 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.51 | -0.51 | -0.6 | -0.52 | -0.001 | 87.18 |
| EPS Diluted
| -0.51 | -0.51 | -0.6 | -0.52 | -0.001 | 87.18 |
| EBITDA
| -74.303 | -54.508 | -47.473 | -13.273 | -9.562 | 626.6 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |